Global /Tunisia /Healthcare /Drug Manufacturers - General /SIPHA

Société des Industries Pharmaceutiques de Tunisie - S.A.

SIPHA

• BVMT: SIPHA • Delayed

4.010TND 0%

1.37 USD

As of 10 June 2026, Société des Industries Pharmaceutiques de Tunisie - S.A. has a market cap of $2.47M USD, ranking #46685 globally and #73 in Tunisia. It ranks #4130 in the Healthcare sector, and #1313 in the Drug Manufacturers - General industry.

Global Rank

46685

Country Rank

Sector Rank

4130

Industry Rank

1313

Key Stats

Market Cap

$2.47MUSD

7.22M TND

Revenue (TTM)

$6.93MUSD

20.23M TND

EBITDA (TTM)

-$4.29MUSD

-12.53M TND

Net Income (TTM)

-$5.86MUSD

-17.1M TND

EBITDA Margin

-62%

Profit Margin

-85%

PS Ratio

0.4

PB Ratio

-0.2

Company Profile

Country (HQ)

Tunisia

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Anis Klouz open_in_new

Employees

744

Founded

1989

Website

siphat.rns.tn open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0%	4.1%	-5.9%	16%	0.3%	6.6%	-37%	15%	-33%

News

Markets

Exchange	Ticker	Price	Quotes
Tunis Stock Exchange (BVMT) MIC: XTUN PRIMARY	SIPHA Societe des Industries Pharmaceutiques de Tunisie-S I PHA T ISIN: TN0006670012 Shares Out.: Shares Outstanding: 1.8M¹ TV: TradingView: BVMT: SIPHA SA: Stock Analysis: BVMT: SIPHA YF: Yahoo Finance: SIPHA GF: Google Finance: BVMT: SIPHA BA: Barron's: SIPHA MS: Morningstar: XTUN: SIPHA	4.010 TND	TV: TradingView: BVMT: SIPHA SA: Stock Analysis: BVMT: SIPHA YF: Yahoo Finance: SIPHA GF: Google Finance: BVMT: SIPHA BA: Barron's: SIPHA MS: Morningstar: XTUN: SIPHA

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Société des Industries Pharmaceutiques de Tunisie - S.A.

Société des Industries Pharmaceutiques de Tunisie - S.A. engages in the research, development, manufacture, packaging, and marketing of pharmaceutical products for human use in Tunisia and internationally. It provides rheumatology drugs, such as MYORELAX, NIFLUMIC, and ALGESAL SURACTIVE; stomatology drugs, including HEXABAIN; and ANALGAN CODEINE 300mg/25mg indicated for the symptomatic treatment of moderate and intense pain. The company was founded in 1989 and is headquartered in Ben Arous, Tunisia.

Similar Companies

Industry: Drug Manufacturers - General (Tunisia)

Name	Market Cap (USD) diff.	PE	Country
Unité de Fabrication des Médicaments S.A BVMT: UMED	$98.45M 287.36M TND 4K%	12.9	Tunisia

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 31M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 22M%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 15M%	97.4	United States
Roche Holding AG SIX: RO	$321.17B 256.25B CHF 13M%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$287.57B 215.59B GBP 12M%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.35B 218.9B CHF 11M%	20.5	Switzerland

chevron_leftBack